Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
http://www.priceseries.com/trade/GLMD-Galmed-Pharmaceuticals-Ltd-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2020040720200423.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments